about
Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in womenZika Virus —10 Public Health Achievements in 2016 and Future PrioritiesDecline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysisVital Signs: Update on Zika Virus–Associated Birth Defects and Evaluation of All U.S. Infants with Congenital Zika Virus Exposure — U.S. Zika Pregnancy Registry, 2016Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis.Molecular epidemiology of the pertussis epidemic in Washington State in 2012.Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosisPopulation diversity among Bordetella pertussis isolates, United States, 1935-2009Sustained Transmission of Pertussis in Vaccinated, 1-5-Year-Old Children in a Preschool, Florida, USA.Pertussis Pseudo-outbreak linked to specimens contaminated by Bordetella pertussis DNA From clinic surfaces.Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States (Including U.S. Territories), July 2017.Pregnancy Outcomes After Maternal Zika Virus Infection During Pregnancy - U.S. Territories, January 1, 2016-April 25, 2017.Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial.Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.Meningococcal disease among men who have sex with men - United States, January 2012-June 2015.Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure - United States, September 2016.Zika Virus Disease Cases - 50 States and the District of Columbia, January 1-July 31, 2016.Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine.Characteristics of Children Aged <18 Years with Zika Virus Disease Acquired Postnatally - U.S. States, January 2015-July 2016.Increased Risk for Meningococcal Disease among Men who have Sex with Men in the United States, 2012-2015.Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College-Rhode Island, 2015-2016.Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.An Assessment of the Cocooning Strategy for Preventing Infant Pertussis-United States, 2011.Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016.Sources of Infant Pertussis Infection in the United States.Evaluation of Level of Agreement in Bordetella Species Identification in Three U.S. Laboratories during a Period of Increased Pertussis.Impact of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccinations on Reported Pertussis Cases Among Those 11 to 18 Years of Age in an Era of Waning Pertussis Immunity: A Follow-up Analysis.Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College - Rhode Island, 2015.Trends in Pertussis Diagnostic Testing in the United States, 1990 to 2012.Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage.Meningococcal Carriage Following a University Serogroup B Meningococcal Disease Outbreak and Vaccination Campaign with MenB-4C and MenB-FHbp - Oregon, 2015-2016.Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA humanEffect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial.Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.Ability To Serologically Confirm Recent Zika Virus Infection in Areas with Varying Past Incidence of Dengue Virus Infection in the United States and U.S. Territories in 2016.Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network.Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana.
P50
Q23924129-B69C4AB8-EBD8-4585-A0FD-3F8E9AB67F73Q28114568-BFB563EE-079D-4096-B12B-FC14AD857743Q28297061-37E5C6D9-78F6-4557-A783-838DD69D7367Q29168666-37EA55EE-2D23-4351-BA29-3B0EA5FEBDC0Q30151997-52AB0BC5-B700-48B7-AD2E-3F5603C5CF9AQ34298066-60A1937D-727E-4FE1-A22D-1F12C2C2A6BEQ34346578-AA6F1E51-9069-4CAF-BB7A-BE812F21DF0BQ34516757-65BCC2DB-681B-4DF9-BD80-A4C3961D1C9EQ34556976-9A4C16CA-20EB-4234-B9E2-416B6269F92BQ36148107-7634F500-0329-4DDA-8D00-7CB22C5696BDQ36525266-ED8F7291-AFC8-4D53-853B-250635B1B034Q37976390-FC7C5533-9D15-4F91-A673-C87D705AD728Q38157323-3FA78CCF-DB2A-40EE-88B0-BC18DFB19136Q38158807-356AB74B-6B2F-45D8-8EA3-8735AD790F20Q38386808-1E6D7448-0FFA-4494-9324-81E52E021099Q38525922-D6D189C7-F98A-49C4-AB58-C9C731C83E91Q38631851-A9988E97-FF08-4B3E-A2E8-2A228C59D756Q38814254-D4C46730-B2CF-4583-BB7D-398F534C2793Q39386989-3E4EE169-499D-44DF-AE96-75D228C7741EQ39869724-610615C5-3EE3-4F1B-87D9-D4F5C9025326Q40054132-15E3DC85-6DFF-4079-97B0-839605F41951Q40201120-CA03C944-6016-43E9-B385-C751A07A2191Q40346821-A5324A9B-10AB-4191-B90F-3AE65B331955Q40402876-F2B42759-7807-4694-A5AF-F7BA673B4F30Q40454304-2D0A8D7B-31A6-4DA4-AD41-E99DCEBDCE3CQ40464630-D9EB1544-F381-46E3-BDF7-70F8C5C2756DQ40564598-46DB8AC0-5210-4E03-A9C7-EB50C88DD0B5Q40673002-3E1CCB67-F744-4934-9101-46753F3E3F3FQ40739286-3F0AEB22-1385-44DB-951E-0C6FF23A02FBQ40842298-2B96A788-1EFD-40DD-8AA2-C0B3A60EA77AQ40975616-F5740E9A-AB31-4FAD-89C5-4CBC2289FBC7Q41259190-E423D29F-C2AE-4D13-8D82-FA1536823474Q41707535-1C9F926E-E5F2-4507-9FAC-8BC03930083EQ41926602-3303D6E8-E68F-4A14-B511-24C4459EAA71Q42217708-807F7FEC-9537-4D5E-AEAF-54ADB11E89E3Q42246468-4DE8A93E-B7C5-48EF-9A7F-F46ED186670EQ42284930-DF4C412C-D6D1-4FCC-A0E9-862893AD0912Q43046934-2624F3B5-2690-4FBB-A17A-313814360FF2Q43230753-9184EC32-F888-45C3-8615-D64726CDA606Q43320957-85E7DC8D-8895-4860-B918-EA55AF7164FD
P50
name
Stacey W Martin
@en
type
label
Stacey W Martin
@en
prefLabel
Stacey W Martin
@en